19609538

Source:http://linkedlifedata.com/resource/pubmed/id/19609538

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0036525, umls-concept:C0069717, umls-concept:C0879262, umls-concept:C0920321, umls-concept:C1522484, umls-concept:C1527249
pubmed:issue	11
pubmed:dateCreated	2009-10-7
pubmed:abstractText	S-1 showed clinical activity in colorectal cancer, and the preclinical data of S-1 with oxaliplatin showed synergistic activity in an animal model. This phase I study was conducted to determine the maximum tolerated dose of S-1 with oxaliplatin and to define its recommended dose for the subsequent phase II study.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8607899
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic, http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations, http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Oxonic Acid, http://linkedlifedata.com/resource/pubmed/chemical/S 1 (combination), http://linkedlifedata.com/resource/pubmed/chemical/Tegafur, http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	1432-1262
pubmed:author	pubmed-author:KangEun MiEM, pubmed-author:KangWon KiWK, pubmed-author:KimHyeong SuHS, pubmed-author:LeeHui YoungHY, pubmed-author:LeeJeeyunJ, pubmed-author:LeeYunaY, pubmed-author:LimHo YeongHY, pubmed-author:ParkJoon OhJO, pubmed-author:ParkMin JaeMJ, pubmed-author:ParkSe HoonSH, pubmed-author:ParkYoung SukYS, pubmed-author:UhmJi EunJE
pubmed:issnType	Electronic
pubmed:volume	24
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1311-6
pubmed:meshHeading	pubmed-meshheading:19609538-Adolescent, pubmed-meshheading:19609538-Adult, pubmed-meshheading:19609538-Aged, pubmed-meshheading:19609538-Antimetabolites, Antineoplastic, pubmed-meshheading:19609538-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:19609538-Colorectal Neoplasms, pubmed-meshheading:19609538-Dose-Response Relationship, Drug, pubmed-meshheading:19609538-Drug Combinations, pubmed-meshheading:19609538-Female, pubmed-meshheading:19609538-Humans, pubmed-meshheading:19609538-Male, pubmed-meshheading:19609538-Middle Aged, pubmed-meshheading:19609538-Neoplasm Metastasis, pubmed-meshheading:19609538-Organoplatinum Compounds, pubmed-meshheading:19609538-Oxonic Acid, pubmed-meshheading:19609538-Recurrence, pubmed-meshheading:19609538-Tegafur, pubmed-meshheading:19609538-Treatment Outcome, pubmed-meshheading:19609538-Young Adult
pubmed:year	2009
pubmed:articleTitle	A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer.
pubmed:affiliation	Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, #50 Ilwon-Dong, Gangnam-Gu, Seoul 135-710, South Korea.
pubmed:publicationType	Journal Article, Clinical Trial, Phase I